ANGLE: Researchers find new use for company's cancer cell harvesting device

Parsortix was used by a Dusseldorf team called Disseminated Cancer Cell Network

blood in testubes
Parsortix has been developed as liquid biopsy system that captures cancer cells from the blood

Using ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) liquid biopsy has been revealed to result in a 30-fold increase in tumour cells harvested for analysis in cancer patients.

Parsortix was deployed by a Düsseldorf team called Disseminated Cancer Cell Network.

READ: ANGLE technology used in cutting-edge research featured in science journal Nature

The researchers and clinicians were attempting to enhance a technique called diagnostic leukapheresis, which harvests circulating tumour cells (CTCSs) to assess how to better treat patients individually.

The increase in the number of CTCs captured by Parsortix was highly effective in reducing the “background” produced by white blood cells caught during the process.

“The Parsortix system provides an easy solution for enriching the sample and harvesting these CTCs keeping the cells alive and undamaged,” said researcher Dr Hans Neubauer.

“The workflow we have developed to culture these cells will allow an intensification of research into new diagnostic and therapeutic solutions."

The results from the work carried out by the Disseminated Cancer Cell Network were peer-reviewed

and published in the periodical Clinical Chemistry. Click here to read.


Quick facts: ANGLE PLC

Price: £0.71

Market: AIM
Market Cap: £121.79 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of ANGLE PLC named herein, including the promotion by the Company of ANGLE PLC in any Content on the Site, the Company receives from said issuer...



Investor Update: Endorsement for Angle's liquid biopsy system Parsortix

Top stories from the Proactive Investors UK newsroom. Angle (LON:AGL) has received an endorsement for its liquid biopsy system Parsortix from European cancer centre UKE, which says it has potential as a biomarker to test for lung cancer. Security group Westminster (LON:WSG) has signed...

on 21/6/19

2 min read